---
title: Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib
  enhances tumor progression in a transgenic mouse model of ÃŸ-cell carcinogenesis
date: '2023-08-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37620408/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230825181111&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) represent a distinct
  hypervascularized tumor entity, often diagnosed at metastatic stage. Therapeutic
  efficacy of anti-angiogenic multi-kinase inhibitors is frequently limited by primary
  or acquired resistance in vivo. This study aimed to characterize the molecular mode
  of action as well as resistance mechanisms to the anti-angiogenic multi-tyrosine
  kinase inhibitor (TKI) Regorafenib in vitro and in ...'
disable_comments: true
---
BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) represent a distinct hypervascularized tumor entity, often diagnosed at metastatic stage. Therapeutic efficacy of anti-angiogenic multi-kinase inhibitors is frequently limited by primary or acquired resistance in vivo. This study aimed to characterize the molecular mode of action as well as resistance mechanisms to the anti-angiogenic multi-tyrosine kinase inhibitor (TKI) Regorafenib in vitro and in ...